Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• The programmed cell death protein (PD-1)/programmed cell death ligand 1 (PD-L1) pathway is crucial for tumor immune evasion.
• PD-1/PD-L1 blocking immunotherapies have improved survival in various cancers.
• However, a significant portion of patients exhibit resistance or disease progression.

Purpose of the Study:

• To review the role of frequently altered protein kinases in tumor cells that impede anti-PD-1/PD-L1 therapy.
• To explore the potential of protein kinase inhibitors (PKIs) in overcoming immunotherapy resistance.

Main Methods:

• Literature review focusing on the interplay between protein kinases and PD-1/PD-L1 pathway.
• Analysis of kinase alterations in tumor cells and their impact on immunotherapy response.

Main Results:

• Altered protein kinases can limit the effectiveness of PD-1/PD-L1 blockade at multiple levels.
• Specific kinases are frequently dysregulated in tumors, contributing to treatment failure.

Conclusions:

• Targeting specific protein kinases may enhance the efficacy of PD-1/PD-L1 immunotherapies.
• Combined therapeutic strategies involving kinase inhibitors and checkpoint blockade warrant further investigation.